Compared with pAAV-GFP-treated hypertensive rats, administration of pAAV-SIRT6 significantly prevented Ang II-mediated pressor response at post 4-week treatment (Figure 1A) and myocardial hypertrophy (Figure 7C) in hypertensive rats with upregulated cardiac levels of ACE2 (Figure 1D) and pAMPKα (Figures 6A, 6B). Here, ACE2 is linked to cardiac hypertrophy.